Literature DB >> 24156012

Synthesis and in vitro pharmacological evaluation of indolyl carboxylic amide analogues as D3 dopamine receptor selective ligands.

Zhude Tu1, Shihong Li, Aixiao Li, Michelle Taylor, David Ho, Maninder Malik, Robert R Luedtke, Robert H Mach.   

Abstract

A series of substituted 1H-indolyl carboxylic acid amides that contain a N-(2-methoxyphenyl)piperazine or N-(2-fluoroethoxy)piperazine group were synthesized and their affinities for human dopamine D2, D3, and D4 receptors were determined. Two of these compounds, 14a and 14b, displayed high binding affinity at D3 (Ki = 0.18 and 0.4 nM, respectively), and selectivity for D3vs. D2 receptors (87-fold and 60-fold, respectively). These two compounds had low binding affinity at D4 receptors and σ receptor sites. The intrinsic activity of these compounds at D2 and D3 receptors was determined using a forskolin-dependent adenylyl cyclase inhibition assay; both 14a and 14b were found to be partial agonists. Furthermore, for compound 14a, the log D value of 2.85 suggested it has suitable lipophilicity for crossing the blood-brain-barrier.

Entities:  

Year:  2013        PMID: 24156012      PMCID: PMC3804115          DOI: 10.1039/C3MD00098B

Source DB:  PubMed          Journal:  Medchemcomm        ISSN: 2040-2503            Impact factor:   3.597


  44 in total

1.  Synthesis and evaluation of 11C- and 18F-labeled 1-[2-(4-alkoxy-3-methoxyphenyl)ethyl]-4-(3-phenylpropyl)piperazines as sigma receptor ligands for positron emission tomography studies.

Authors:  Kazunori Kawamura; Philip H Elsinga; Tadayuki Kobayashi; Shin-ichi Ishii; Wei-Fang Wang; Kiyoshi Matsuno; Willem Vaalburg; Kiichi Ishiwata
Journal:  Nucl Med Biol       Date:  2003-04       Impact factor: 2.408

2.  Conformationally-flexible benzamide analogues as dopamine D3 and sigma 2 receptor ligands.

Authors:  Robert H Mach; Yunsheng Huang; Rebekah A Freeman; Li Wu; Suwanna Vangveravong; Robert R Luedtke
Journal:  Bioorg Med Chem Lett       Date:  2004-01-05       Impact factor: 2.823

Review 3.  Progress in developing D3 dopamine receptor ligands as potential therapeutic agents for neurological and neuropsychiatric disorders.

Authors:  Robert R Luedtkea; Robert H Mach
Journal:  Curr Pharm Des       Date:  2003       Impact factor: 3.116

Review 4.  Recent advances in the development of dopamine D(3) receptor agonists and antagonists.

Authors:  A M Crider; M A Scheideler
Journal:  Mini Rev Med Chem       Date:  2001-05       Impact factor: 3.862

Review 5.  [Central dopamine receptors: general considerations (Part 1)].

Authors:  R Bordet
Journal:  Rev Neurol (Paris)       Date:  2004-09       Impact factor: 2.607

6.  Endogenous dopamine (DA) competes with the binding of a radiolabeled D₃ receptor partial agonist in vivo: a positron emission tomography study.

Authors:  Robert H Mach; Zhude Tu; Jinbin Xu; Shihong Li; Lynne A Jones; Michelle Taylor; Robert R Luedtke; Colin P Derdeyn; Joel S Perlmutter; Mark A Mintun
Journal:  Synapse       Date:  2011-03-21       Impact factor: 2.562

Review 7.  The renal dopamine receptors.

Authors:  P A Jose; J R Raymond; M D Bates; A Aperia; R A Felder; R M Carey
Journal:  J Am Soc Nephrol       Date:  1992-02       Impact factor: 10.121

8.  Autoradiographic localisation of D3-dopamine receptors in the human brain using the selective D3-dopamine receptor agonist (+)-[3H]PD 128907.

Authors:  H Hall; C Halldin; D Dijkstra; H Wikström; L D Wise; T A Pugsley; P Sokoloff; S Pauli; L Farde; G Sedvall
Journal:  Psychopharmacology (Berl)       Date:  1996-12       Impact factor: 4.530

9.  Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A.

Authors:  C Reavill; S G Taylor; M D Wood; T Ashmeade; N E Austin; K Y Avenell; I Boyfield; C L Branch; J Cilia; M C Coldwell; M S Hadley; A J Hunter; P Jeffrey; F Jewitt; C N Johnson; D N Jones; A D Medhurst; D N Middlemiss; D J Nash; G J Riley; C Routledge; G Stemp; K M Thewlis; B Trail; A K Vong; J J Hagan
Journal:  J Pharmacol Exp Ther       Date:  2000-09       Impact factor: 4.030

10.  N-(4-(4-(2,3-dichloro- or 2-methoxyphenyl)piperazin-1-yl)butyl)heterobiarylcarboxamides with functionalized linking chains as high affinity and enantioselective D3 receptor antagonists.

Authors:  Amy Hauck Newman; Peter Grundt; George Cyriac; Jeffrey R Deschamps; Michelle Taylor; Rakesh Kumar; David Ho; Robert R Luedtke
Journal:  J Med Chem       Date:  2009-04-23       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.